Smith George M, Strunz Celia
Department of Physiology, University of Kentucky, Albert B. Chandler Medical Center, Lexington, KY 40536-0298, USA.
Glia. 2005 Nov 15;52(3):209-18. doi: 10.1002/glia.20236.
After injury to the adult central nervous system (CNS), numerous cytokines and growth factors are released that contribute to reactive gliosis and extracellular matrix production. In vitro examination of these cytokines revealed that the presence of transforming growth factor-beta1 (TGF-beta1) and epidermal growth factor (EGF) greatly increased the production of several chondroitin sulfate proteoglycans (CSPG) by astrocytes. Treatment of astrocytes with other EGF-receptor (ErbB1) ligands, such as TGF-alpha and HB-EGF, produced increases in CSPG production similar to those observed with EGF. Treatment of astrocytes, however, with heregulin, which signals through other members of the EGF-receptor family (ErbB2, ErbB3, ErbB4), did not induce CSPG upregulation. The specificity of activation through the ErbB1 receptor was further verified by using a selective antagonist (AG1478) to this tyrosine kinase receptor. Western blot analysis of astrocyte supernatant pre-digested with chondroitinase ABC indicated the presence of multiple core proteins containing 4-sulfated or 6-sulfated chondroitin. To identify some of these CSPGs, Western blots were screened using antibodies to several known CSPG core proteins. These analyses showed that treatment of astrocytes with EGF increased phosphacan expression, whereas treatment with TGF-beta1 increased neurocan expression. Reverse transcription-polymerase chain reaction (RT-PCR) was used to examine the expression of these molecules in vivo, which result in increased expression of TGF-beta1, EGF-receptor, neurocan, and phosphacan after injury to the brain. These data begin to elucidate some of the injury-induced growth factors that regulate the expression of CSPGs which could be targeted in the future to modulate CSPG production after injury to the central nervous system.
在成体中枢神经系统(CNS)损伤后,会释放出多种细胞因子和生长因子,它们会导致反应性胶质增生和细胞外基质的产生。对这些细胞因子的体外研究表明,转化生长因子-β1(TGF-β1)和表皮生长因子(EGF)的存在极大地增加了星形胶质细胞产生几种硫酸软骨素蛋白聚糖(CSPG)的量。用其他表皮生长因子受体(ErbB1)配体,如转化生长因子-α(TGF-α)和肝素结合表皮生长因子(HB-EGF)处理星形胶质细胞,会使CSPG的产生增加,其增加程度与用EGF处理时观察到的相似。然而,用在这里通过表皮生长因子受体家族的其他成员(ErbB2、ErbB3、ErbB4)发出信号的神经调节蛋白处理星形胶质细胞,并未诱导CSPG上调。通过使用针对该酪氨酸激酶受体的选择性拮抗剂(AG1478),进一步验证了通过ErbB1受体激活的特异性。用硫酸软骨素酶ABC预先消化的星形胶质细胞上清液的蛋白质印迹分析表明存在多种含有4-硫酸化或6-硫酸化软骨素的核心蛋白。为了鉴定其中一些CSPG,使用针对几种已知CSPG核心蛋白的抗体对蛋白质印迹进行筛选。这些分析表明,用EGF处理星形胶质细胞会增加磷蛋白聚糖的表达,而用TGF-β1处理会增加神经蛋白聚糖的表达。逆转录-聚合酶链反应(RT-PCR)用于检测这些分子在体内的表达,结果显示脑损伤后TGF-β1、表皮生长因子受体、神经蛋白聚糖和磷蛋白聚糖的表达增加。这些数据开始阐明一些损伤诱导的生长因子,它们调节CSPG的表达,未来可以针对这些因子来调节中枢神经系统损伤后CSPG的产生。